Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
The invention relates to the field of hematopoietic CD34 + cell mobilization. In particular, this invention relates to a method for increasing the mobilization of pluripotent hematopoietic CD34 + cells by administration of human growth hormone or one of its derivates to the individual.
1 . A method for preparing a population of circulating CD34 + cells which regenerate hematopoiesis in vivo, comprising:
a) administering to a donor a composition comprising growth hormone or one of its derivatives having the activity of growth hormone or any factor inducing growth hormone release, simultaneously or separately with a composition comprising G-CSF, in an amount sufficient to enhance the mobilization or peripheralization effect of G-CSF to further increase in said donor the number of circulating CD34 + cells which regenerate hematopoiesis in vivo beyond that achieved by G-CSF alone; and
b) isolating a population of circulating CD34 + cells which regenerate hematopoiesis in vivo from the peripheral blood of said donor.
2 . The method according to claim 1 , wherein the increased number of CD34 + cells is more than 10, 25, 34 or 80 CD34 + cells per microliter of donor peripheral blood.
3 . The method according to claim 1 , wherein the increased number of CD34 + cells is at least 2×10 6 , 4×10 6 , 5×10 6 , 6×10 6 , 8×10 6 , 15×10 6 CD34 + cells per kilogram of donor body weight.
4 . The method according to claim 1 , wherein the increased number of circulating CD34 + cells which regenerate hematopoiesis in vivo corresponds to about 500 or more CFU-GM per milliliter of donor peripheral blood.
5 . The method according to claim 1 , wherein the increased number of circulating CD34 + cells which regenerate hematopoiesis in vivo corresponds to an increased level of CFU-C, CFU-Meg or BFU-E in donor peripheral blood.
6 . The method according to claim 1 , wherein the increased number of circulating CD34 + cells which regenerate hematopoiesis in vivo substantially corresponds to a white blood cell count of about 1000 or more cells per microliter of donor peripheral blood.
7 . The method according to claim 1 , wherein the increased number of circulating CD34 + cells which regenerate hematopoiesis in vivo corresponds to about 1×10 5 or more GM-CFC per kilogram of donor or recipient body weight.
8 . The method according to claim 1 , wherein the circulating CD34 + cells which regenerate hematopoiesis in vivo are CD34 + /CD33 + cells and/or CD34 + /CD38 − cells and/or CD34 + /Thy-I cells and/or CD34 + /Thy-I/CD38 − cells and/or bone-marrow stem cells and/or progenitor cells and/or long-term culture initiating cells (LTC-IC) and/or cells that fulfill self renewal potential and/or cells that fulfill pluripotential characteristics and/or cells that initiate long term bone marrow culture and/or cells that can generate multiple cell lineages.
9 . The method according to claim 1 , wherein the target number of circulating CD34 + cells which regenerate hematopoiesis in vivo is at least 2×10 4 LTC-IC per kg of donor or recipient body, about 2×10 6 or more CD34 + cells per kilogram of donor or recipient body weight, about 4×10 6 or more CD34 + cells per kilogram of donor or recipient body weight or about 8×10 6 or more CD34 + cells per kilogram of donor or recipient body weight.
10 . The method according to claim 1 , wherein the volume of blood processed in step (b) is in a range of about 30 to about 900 milliliters.
11 . The method according to claim 1 , wherein growth-hormone or one of its derivatives or any factor inducing growth hormone release is administered in an amount between 20 to 50 μg/kg of donor body weight, in an amount between 30 to 40 μg/kg of donor body weight or in an amount of 33 μg per kilogram of donor body weight.
12 . The method according to claim 1 , wherein the G-CSF is administered in an amount between 3 to 15 μg/kg of donor body weight, in an amount between 4 to 12 μg/kg of donor body weight or in an amount of around 5 or 10 μg per kilogram of donor body weight.
13 . The method according to claim 1 , wherein the administration of Growth Hormone is made three times a day and the administration of G-CSF is made daily.
14 . The method according to claim 1 , wherein the administration of said composition is made by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal or buccal routes.
15 . The method according to claim 1 , wherein the administration of said composition is daily or three times a day.
16 . The method according to claim 1 , wherein the administration of said composition is made over a period of 5 days or over a period of 10 days.
17 . The method according to claim 1 , wherein the administration begins around 7 days after the beginning of a chemotherapeutic treatment or around 2 days after the end of a chemotherapeutic treatment.
18 . The method according to claim 1 , wherein the growth hormone is a recombinant growth hormone.
19 . The method according to claim 1 , wherein the growth hormone is human growth hormone.
20 . The method according to claim 1 , wherein said growth hormone or one of its derivatives or any factor inducing growth hormone release is administered at a different time than said composition comprising G-CSF.
21 . The method according to claim 1 , wherein said growth hormone or one of its derivatives or any factor inducing growth hormone release is administered simultaneously with said composition comprising G-CSF.